Here are three ALD developments from September 2026. Each one includes who it applies to and a link to the original source. Europe approves a first drug treatment for boys with cerebral ALD What happened: The European Commission approved NEZGLYAL (leriglitazone) on September 21, 2026. It is the first approved drug treatment for cerebral ALD in the EU. minoryx Who it’s for: Boys ages 2 to 12 with cerebral ALD who have gadolinium-negative (non-enhancing) brain lesions on MRI an